Q-omics provides the consensus-scored C10orf62 profile across patient tissues and cancer cell-line models. C10orf62 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, C10orf62 is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, C10orf62 RNA expression shows 11,164 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight UVM, KICH, and PDAC as cancer lineages where C10orf62 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C10orf62 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C10orf62 survival associations across molecular data types. C10orf62 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C10orf62 RNA expression–survival associations across cancer types. High C10orf62 expression shows unfavorable associations in UVM, UCEC, COAD, UCS and LUAD, but favorable associations in LUSC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for C10orf62 RNA expression.
This table summarizes C10orf62 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for C10orf62. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C10orf62 shows lower tumor expression in KICH, KIRC and THCA and higher tumor expression in BLCA, COAD and LIHC. The KICH box plot shows higher C10orf62 RNA expression in normal versus tumor tissue (log2 FC = −0.419, t-test p < 0.001).
This table shows molecular features associated with C10orf62 in patient tissues and cancer cell lines. In patient samples, C10orf62 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, C10orf62 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
